Learn · Topic guide

Longevity & Senescence Peptides Explained

Aging research has converged on a short list of cellular processes that change with chronological time: telomeres shorten with each division, mitochondria signal differently under metabolic stress, and the redox cofactor NAD shifts in availability. Several peptides studied in laboratory settings intersect with these pathways, which is why they recur in gerontology-focused literature. This reference article surveys the in-vitro and receptor-signaling framing behind two peptides in our dataset that appear in longevity research contexts: Epitalon, a synthetic pineal tetrapeptide associated with telomerase regulation in cultured cells, and MOTS-c, a mitochondrial-derived peptide linked to AMPK signaling. It also explains the broader NAD biology that frames much longevity discussion, kept distinct from any specific peptide claim. Everything here describes cell-culture observations, enzymatic assays, and structural biology, not health outcomes. No dosing, therapeutic, or personal-use guidance is offered or implied. The aim is to give researchers an accurate, source-grounded map of how these molecules are positioned within senescence and longevity science as laboratory reagents.

Research use onlyStart reading ↓

Key takeaways

Replicative senescence in cultured cells tracks with telomere shortening; telomerase (hTERT) and the recombination-based ALT pathway are the two routes by which telomere length is maintained, and both appear in longevity peptide literature.
Epitalon (AEDG tetrapeptide; C14H22N4O9; 390.35 g/mol; CAS 307297-39-8) is reported in vitro to induce hTERT expression and telomerase activity in telomerase-negative human fetal fibroblasts, with telomere elongation attributed to ALT in some cancer cell lines.
Epitalon has no well-defined membrane receptor; its proposed mechanism is chromatin-level peptide-DNA and peptide-histone interaction with gene-expression modulation, distinguishing it from receptor-targeted dataset peptides.
NAD biology and the NAD+/NADH ratio are a general longevity-research framework tied to energy sensing and sirtuins; no peptide in this dataset is a NAD precursor or direct NAD-pathway reagent.
MOTS-c is a 16-residue mitochondrial-derived peptide (CAS 1627580-64-6) that activates AMPK non-canonically via folate-cycle modulation and AICAR accumulation, linking it to metabolic and redox longevity research.
All findings described are cell-culture, enzymatic-assay, and structural observations; none constitutes evidence of extended lifespan or any health outcome.

Section 01

The Senescence Framework: Telomeres and Replicative Limits

Replicative senescence is one of the oldest experimental concepts in cell biology.

Replicative senescence is one of the oldest experimental concepts in cell biology. Cultured somatic cells divide a finite number of times before halting, and that limit tracks with progressive shortening of telomeres, the repetitive DNA caps on chromosome ends. Telomerase, the enzyme whose catalytic subunit is encoded by hTERT, can counteract this shortening by extending telomeric repeats, but most somatic cells keep telomerase switched off. This on-off biology is the backdrop against which longevity-oriented peptide research is read. The question researchers ask in vitro is whether a given molecule influences hTERT expression, measurable telomerase activity (commonly via the TRAP assay), or telomere length in a defined cell line. These are biochemical readouts performed on cells in dishes, not statements about organismal aging. The senescence framework also includes alternative lengthening of telomeres (ALT), a recombination-based, telomerase-independent route to telomere maintenance seen in certain cancer cell lines. Distinguishing telomerase-mediated from ALT-mediated effects matters when interpreting any reported telomere elongation, because the two mechanisms have very different biological implications and are studied with different controls.

Section 02

Epitalon and the Telomerase Question

Epitalon is a synthetic linear tetrapeptide with the sequence Ala-Glu-Asp-Gly (AEDG), molecular formula C14H22N4O9 and a molecular weight of 390.

Epitalon is a synthetic linear tetrapeptide with the sequence Ala-Glu-Asp-Gly (AEDG), molecular formula C14H22N4O9 and a molecular weight of 390.35 g/mol (PubChem CID 219042; CAS 307297-39-8). It was developed by the Khavinson group at the St. Petersburg Institute of Bioregulation and Gerontology and is modeled on the amino-acid composition of the pineal extract epithalamin. Its laboratory profile is what places it in longevity discussions. In telomerase-negative human fetal fibroblast cultures, the peptide has been reported to induce hTERT expression, increase telomerase enzymatic activity by TRAP assay, and extend telomere length (Khavinson et al. 2003, PMID 12937682). In some cancer cell lines, reported telomere elongation has instead been attributed to ALT activity (Al-dulaimi et al. 2025, PMID 40908429). Unlike receptor-targeted peptides, Epitalon has no well-defined membrane receptor or second-messenger cascade. Fluorescently labeled AEDG penetrates the cytoplasm and nucleus of cultured cells and binds deoxyribooligonucleotides and DNA in a sequence-specific manner, which underpins a proposed epigenetic, chromatin-level mode of action rather than canonical receptor signaling.

Section 03

Beyond Telomeres: Epitalon's Gene-Expression Profile

Telomerase is only one readout reported for this tetrapeptide in cell-based work.

Telomerase is only one readout reported for this tetrapeptide in cell-based work. In cultured human mesenchymal stem cells, the peptide has been associated with increased mRNA and protein levels of neurogenic differentiation markers, including Nestin, GAP43, beta-Tubulin III, and Doublecortin (Khavinson et al. 2020, PMID 32019204). Other model-system readouts include altered IL-2 mRNA and antioxidant-related measures. Taken together, these observations describe a molecule whose proposed activity is transcriptional and translational modulation, consistent with the direct peptide-DNA and peptide-histone interactions documented by Fedoreyeva et al. (2011, PMID 22117547). For research framing, the important point is that the defined signaling pathway remains incompletely characterized. Current models emphasize chromatin-level interaction and gene-expression modulation rather than a specific receptor or kinase cascade. That distinguishes Epitalon from the growth-hormone-axis secretagogues and incretin peptides in the same dataset, which act through well-mapped class B GPCRs. Researchers working with the tetrapeptide therefore treat it as an epigenetic-modulation reagent in senescence and gerontology cell models, with the literature still building toward a mechanistic consensus.

Section 04

NAD Biology: The Metabolic Side of Longevity Research

Where peptides intersect this territory is through downstream energy-sensing nodes rather than NAD itself.

Much longevity discussion centers not on telomeres but on NAD, the nicotinamide adenine dinucleotide cofactor that shuttles electrons in central metabolism and serves as a substrate for sirtuins and other enzymes. As a general principle of cell biology, NAD availability and the NAD+/NADH ratio influence energy-sensing pathways, and declining NAD pools are a recurring theme in aging-cell literature. This is stated here as a broad scientific framework, not as a property of any peptide in our dataset; none of the dataset entries is a NAD precursor or a direct NAD-pathway reagent. Where peptides intersect this territory is through downstream energy-sensing nodes rather than NAD itself. AMP-activated protein kinase (AMPK) is the canonical cellular energy sensor, and it sits at the junction where metabolic-stress signaling and longevity research overlap. A molecule that activates AMPK in cultured cells is, by that fact alone, of interest to metabolism and aging researchers. That is the bridge from NAD-centric framing to the mitochondrial-derived peptide discussed next, keeping the distinction clear between general principle and dataset-specific claim.

Section 05

MOTS-c: A Mitochondrial-Derived Peptide in Energy Signaling

MOTS-c is a 16-residue microprotein (sequence MRWQEMGYIFYPRKLR; C101H152N28O22S2; 2174.

MOTS-c is a 16-residue microprotein (sequence MRWQEMGYIFYPRKLR; C101H152N28O22S2; 2174.62 g/mol; CAS 1627580-64-6) encoded by a short open reading frame within the mitochondrial 12S rRNA (MT-RNR1) gene. It was identified in 2015 by Changhan Lee in the Pinchas Cohen laboratory at the USC Leonard Davis School of Gerontology (Lee et al. 2015, PMID 25738459), a gerontology lineage that situates it squarely in longevity research. In cell-culture systems, MOTS-c modulates the cytosolic folate-methionine one-carbon cycle; by attenuating de novo purine biosynthesis it promotes accumulation of AICAR, an allosteric AMPK activator. This is a non-canonical route to AMPK signaling, largely independent of acute AMP:ATP ratio changes. Under metabolic stress in vitro, MOTS-c translocates from cytosol to nucleus in an AMPK-dependent manner and associates with stress-responsive transcription factors including NRF2 at antioxidant-response elements (Kim et al. 2018, PMID 29983246). Reported readouts in model systems include AMPK phosphorylation and altered mitonuclear transcriptional crosstalk. These are mechanistic observations in cells and animal tissue, not statements of clinical efficacy.

Section 06

Reading Longevity Peptide Claims Critically

Longevity is a domain where laboratory findings are easily over-read.

Longevity is a domain where laboratory findings are easily over-read. Several discipline points help keep interpretation honest. First, level of evidence: a TRAP-assay result in one fibroblast line is a biochemical observation, not a demonstration of extended cellular or organismal lifespan. Second, mechanism specificity: telomere elongation attributed to telomerase versus ALT carries different meaning, and Epitalon's literature reports both depending on the cell line. Third, the absence of a defined receptor for Epitalon means its proposed epigenetic mechanism is still being mapped, so confident mechanistic statements should be hedged accordingly. Fourth, framing discipline around NAD: it is a genuine longevity-research theme, but it is a general cofactor-biology principle, not a property of the peptides catalogued here, and conflating the two is a common error. Finally, MOTS-c's AMPK link is well-described in cell and animal models but should not be extrapolated past those systems. For research-use audiences, the value of these molecules lies in their defined in-vitro behavior, the cell lines and assays in which it was observed, and the primary citations that anchor each claim.

Straight answers

Frequently asked questions

What is Epitalon's amino-acid sequence and molecular identity?

Epitalon is a synthetic linear tetrapeptide with the sequence Ala-Glu-Asp-Gly (AEDG), one-letter A-E-D-G. Its molecular formula is C14H22N4O9, its molecular weight is 390.35 g/mol, its CAS number is 307297-39-8, and its PubChem CID is 219042. It is a synthetic pineal tetrapeptide modeled on the amino-acid composition of epithalamin, developed by the Khavinson group at the St. Petersburg Institute of Bioregulation and Gerontology.

What does the in-vitro telomerase data on Epitalon actually show?

In telomerase-negative human fetal fibroblast cultures, the peptide is reported to induce expression of the catalytic subunit hTERT, increase telomerase enzymatic activity measured by the TRAP assay, and extend telomere length (Khavinson et al. 2003, PMID 12937682). In some cancer cell lines, reported telomere elongation has instead been attributed to alternative lengthening of telomeres (ALT) rather than telomerase. These are cell-culture and enzymatic-assay observations only.

Does Epitalon act through a specific receptor?

No well-defined membrane receptor or second-messenger pathway has been characterized for Epitalon. Fluorescently labeled AEDG penetrates the cytoplasm and nucleus of cultured cells and binds DNA and deoxyribooligonucleotides in a sequence-specific manner. Current models emphasize a direct chromatin-level interaction and epigenetic gene-expression modulation rather than canonical receptor signaling.

Is NAD a peptide, and which dataset peptide affects NAD?

NAD (nicotinamide adenine dinucleotide) is a metabolic cofactor, not a peptide. It is discussed here as a general longevity-research framework relating to energy sensing and sirtuin biology. None of the peptides in this dataset is a NAD precursor or a direct NAD-pathway reagent. Peptides intersect this area only through downstream energy-sensing nodes such as AMPK.

How is MOTS-c connected to longevity research?

MOTS-c is a 16-residue mitochondrial-derived peptide (sequence MRWQEMGYIFYPRKLR; CAS 1627580-64-6) encoded within the mitochondrial 12S rRNA gene and discovered in 2015 in a gerontology laboratory at USC. In cell-culture systems it activates AMPK non-canonically by modulating the folate one-carbon cycle and promoting AICAR accumulation, and under metabolic stress it translocates to the nucleus and associates with NRF2 at antioxidant-response elements (Kim et al. 2018, PMID 29983246).

What distinguishes telomerase-mediated from ALT-mediated telomere elongation?

Telomerase-mediated elongation uses the enzyme telomerase, whose catalytic subunit is hTERT, to add telomeric repeats. ALT (alternative lengthening of telomeres) is a recombination-based, telomerase-independent mechanism observed in certain cancer cell lines. The distinction matters because the two routes are studied with different controls and carry different biological implications when interpreting any reported telomere change.

Are these peptides established longevity reagents with proven effects?

The findings described are confined to in-vitro cell-culture work, enzymatic assays such as TRAP, and structural and gene-expression studies, plus animal-tissue models for MOTS-c. They are mechanistic, model-system observations of signaling and biochemical behavior. They do not demonstrate extended cellular or organismal lifespan and are not statements of any health outcome.

Keep exploring

Continue learning

Topic guideWhat Are Research Peptides?Research peptides are short chains of amino acids studied in the laboratory to understand how cells receive, interpret, and relay molecular signals. Because peptides sit at the size boundary between simple amino acids and large folded proteins, they make precise tools for asking narrow biochemical questions: which receptor does a given sequence engage, what second messenger rises inside the cell, and how does a small change to the chain alter that behavior? This reference looks at what defines a peptide, how peptides differ from proteins, what the label "research use only" (RUO) means, and why these molecules are examined in cell-based and cell-free systems rather than treated as finished products. Throughout, the framing is strictly in-vitro and receptor-signaling: the discussion concerns binding assays, cultured cells, isolated tissues, and structure-activity studies. Specific peptide facts cited here are drawn from a curated reference dataset of characterized research peptides. General principles of peptide chemistry are presented as established background. Nothing here describes administration, outcomes, or use in people; the goal is conceptual literacy for laboratory and educational contexts.Read →Topic guidePeptide Classes ExplainedPeptides are short chains of amino acids, and in laboratory research they are rarely studied as an undifferentiated group. Investigators sort them by what they do at the molecular level: which receptor they bind, which intracellular cascade they trigger, or which biochemical process they modulate in a cell-free or cultured-cell system. This reference organizes a set of research peptides by functional class rather than by chemical size or origin. The groupings used here are growth hormone secretagogues, incretin-receptor agonists, regenerative and matrix-signaling peptides, nootropic neuropeptides, cosmetic matricellular peptides, and mitochondrial-derived peptides. Each class is defined by a shared mechanistic signature observed in receptor-binding assays, second-messenger readouts, or gene-expression profiling. Every peptide-specific statement below is drawn from a curated dataset of in-vitro and structural findings, and the framing is strictly that of laboratory research: receptor occupancy, signal transduction, and biochemical activity. No human dosing, clinical outcome, or disease-treatment interpretation is offered. The goal is a clear conceptual map of how research peptides differ in molecular target and signaling logic.Read →Topic guideGrowth Hormone Secretagogues ExplainedGrowth hormone secretagogues (GHS) are a research category defined by mechanism rather than chemistry: each is a molecule that, in laboratory and cell-based systems, prompts pituitary somatotroph cells to release stored growth hormone instead of supplying growth hormone from outside the system. The category splits cleanly into two receptor branches. One branch acts at the growth hormone-releasing hormone receptor (GHRH-R); the other acts at the growth hormone secretagogue receptor type 1a (GHS-R1a), the receptor for endogenous ghrelin. These two receptors sit on the same cells but run through different G-protein cascades, which is why the distinction matters at the bench. This reference article explains GHS-R1a signaling, contrasts GHRH analogs with ghrelin-mimetic growth hormone-releasing peptides (GHRPs), describes why GH release is pulsatile, and clarifies the conceptual line between a secretagogue and an exogenous hormone. All statements here are framed strictly around in-vitro and receptor-signaling observations in research models. Peptide-specific facts are drawn only from a controlled reference dataset; broader statements are presented as general principles of peptide endocrinology, not as claims about any outcome.Read →Topic guideGHRH Analogs vs GHRPsTwo families of research peptides frequently appear together in growth-hormone-axis signaling studies: growth-hormone-releasing hormone (GHRH) analogs and growth-hormone-releasing peptides (GHRPs). Although both are described in the literature as growth hormone secretagogues, they engage entirely different cell-surface receptors and trigger different intracellular second-messenger cascades in laboratory models. GHRH analogs such as sermorelin and CJC-1295 act at the GHRH receptor (GHRHR), a class B Gs-coupled G-protein-coupled receptor on pituitary somatotroph cells. GHRPs such as GHRP-2 act at the growth hormone secretagogue receptor type 1a (GHS-R1a) - the ghrelin receptor - a class A GPCR coupled to a separate signaling arm. This article compares the two receptor systems as characterized in in-vitro and ex-vivo work, explains why their pathways are described as complementary, and grounds each peptide-specific claim in the reference dataset. The framing throughout is strictly receptor-signaling and laboratory-research: cAMP and calcium readouts in cultured cells, binding constants, and structure-activity relationships, not clinical outcomes. Understanding the receptor-level distinction clarifies why these two peptide classes are studied as separate but convergent inputs onto the somatotroph.Read →

For in-vitro laboratory research use only. Not for human or animal consumption. Educational content, not medical advice; not intended to diagnose, treat, cure, or prevent any disease. Not evaluated by the FDA.